Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 51c; Lifts Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $215.98 +3.92%
EPS Growth %: -22.5%
Financial Fact:
Selling, general and administrative: 124.37M
Today's EPS Names:
OPY, BNCC, ZVOI, More
EPS Growth %: -22.5%
Financial Fact:
Selling, general and administrative: 124.37M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $5.17, $0.51 better than the analyst estimate of $4.66. Revenue for the quarter came in at $940.65 million versus the consensus estimate of $939.97 million.
GUIDANCE:
Jazz Pharmaceuticals raises FY2022 revenue midpoint to $3.65 billion, versus the consensus of $3.65 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Jazz Pharmaceuticals (JAZZ) PT Raised to $300 at JPMorgan
- Red River Bancshares, Inc. (RRBI) Tops Q3 EPS by 7c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
